We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: A pilot study in two cases.
- Authors
Bai, Juan; Su, Wang; Fang, Hong; Qiao, Jianjun
- Abstract
(c) Graph of the improvement of pruritus evaluated in NRS gl No treatment-associated adverse effects were observed in the two patients while receiving therapy with abrocitinib. Primary cutaneous lichenoid amyloidosis (PCLA) is featured by the deposition amyloid, originated from keratinocytes within the papillary dermis and lacking systemic involvement.[1] Various therapies including topical and intralesional corticosteroids, systemic retinoids, psoralen 1 ultraviolet A and UVB phototherapy, cyclosporine, cryosurgery, dupilumab, Janus kinase (JAK) inhibitors, and surgical interventions and lasers have been used for treating PCLA.[[1]] Current treatments are based on case reports and off-label trails, and standardized treatment has not been established. Lichen amyloidosis is a common variant of PCLA in which pruritus is intense or a predominant symptom.[[1], [4]] In our reports, recalcitrant chronic itch in two patients that failed other therapies markedly improved when treated with abrocinitib.
- Subjects
CARDIAC amyloidosis; ITCHING; AMYLOIDOSIS; PILOT projects
- Publication
International Journal of Dermatology, 2023, Vol 62, Issue 9, pe480
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16698